GMAB
Genmab ASNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$16.45B
P/E Ratio
17.40
EPS
$1.54
Beta
0.74
52W High
$35.43
52W Low
$18.89
50-Day MA
$27.59
200-Day MA
$28.71
Dividend Yield
—
Profit Margin
25.90%
Forward P/E
15.77
PEG Ratio
1.69
About Genmab AS
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Fundamentals
| Revenue (TTM) | $3.72B |
| Gross Profit (TTM) | $3.48B |
| EBITDA | $1.29B |
| Operating Margin | 23.00% |
| Return on Equity | 17.50% |
| Return on Assets | 8.10% |
| Revenue/Share (TTM) | $5.99 |
| Book Value | $9.49 |
| Price-to-Book | 2.80 |
| Price-to-Sales (TTM) | 4.42 |
| EV/Revenue | 5.41 |
| EV/EBITDA | 15.06 |
| Quarterly Earnings Growth (YoY) | -94.40% |
| Quarterly Revenue Growth (YoY) | 3.00% |
| Shares Outstanding | $613.91M |
| Float | $60.89M |
| % Insiders | 0.00% |
| % Institutions | 12.10% |
Historical Volatility
HV 10-Day
31.24%
HV 20-Day
31.69%
HV 30-Day
28.68%
HV 60-Day
30.68%
HV Rank
16.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($37.68 target)
8
Buy3
HoldData last updated: 4/29/2026